Virus Protease Inhibitor

ZIKV-IN-2 (compound 3a) is a potent ZIKV NS5 methyl transferase (MTase) inhibitor with an IC₅₀ value of 38.86 μM. ZIKV-IN-2 inhibits ZIKV replication and infection. ZIKV-IN-2 can be used in research of Zika virus (ZIKV).

ASAP-0036543 is an orally active virus NS2B-NS3 protease inhibitor. ASAP-0036543 exhibits activity againse Zika virus (ZIKV) and West Nile virus (WNV). ASAP-0036543 reduces ZIKV RNA load in plasma and spleen, and inhibits ZIKV and WNV replication in mammalian cells. ASAP-0036543 can be used for the research of zika virus infection, west nile virus infection.

CGP 53437 is an orally active HIV-1 protease inhibitor, with a K_i of 0.2 nM. CGP 53437 delays the onset of HIV replication.

LabMol-301 inhibits both NS5 RdRp and NS2B-NS3pro activity (IC₅₀: 0.8 and 7.4 μM, respectively). LabMol-301 has a cytoprotective effect and prevents Zika virus (ZIKV)-induced cell death.

Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation.

SARS-CoV-2 Mpro-IN-45 (compound 28f) is an orally active Mpro inhibitor with IC₅₀ values of 0.12 and 0.16 μM for HCoV-OC43 Mpro and SARS-CoV-2 Mpro, respectively. SARS-CoV-2 Mpro-IN-45 exhibits antiviral activity.

SARS-CoV-2 PLpro-IN-2 (Compound 12) is a highly selective SARS-CoV-2 papain-like protease (PLpro) inhibitor of (IC₅₀=0.06 μM). SARS-CoV-2 PLpro-IN-2 inhibits viral replication and immune evasion. SARS-CoV-2 PLpro-IN-2 exhibits antiviral efficacy in HeLa-ACE2 cells (EC₅₀=2.9 μM). SARS-CoV-2 PLpro-IN-2 is promising for research of COVID-19.

Herpes virus inhibitor 1 is a herpes virus inhibitor and disrupts herpes virus ribonucleotide reductase quaternary structure. Herpes virus inhibitor 1 inhibits viral replication.

Flaviviruses-IN-2 (compound 78) is a potent flaviviruses inhibitor. Flaviviruses-IN-2 reduces the WNV (West Nile virus) protease activity, with inhibition of 56%.

Lycorine (hydrochloride) (Standard) is the analytical standard of Lycorine (hydrochloride). This product is intended for research and analytical applications. Lycorine hydrochloride is the main active ingredient of the herbal medicine derived from Lycoris radiata (L’Her.) Herb. and is also a melanoma vasculogenic inhibitor and has anti-tumor activity. Lycorine hydrochloride effectively inhibits mitotic proliferation of Hey1B cells (IC50 of 1.2 μM).

CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC₅₀: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC₅₀: 63.28 μM).

Palmatine (chloride) (Standard) is the analytical standard of Palmatine (chloride). This product is intended for research and analytical applications. Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.

2-Hydroxy-4-methylbenzenesulphonic acid ammonium is an impurity of Policresulen. Policresulen is a potent NS2B/NS3 protease inhibitor with an IC₅₀ of 0.48 μg/mL. Policresulen effectively inhibits the replication of DENV2 virus in BHK-21 cells with an IC₅₀ of 4.99 μg/mL. Policresulen acted as a competitive inhibitor of the protease, and slightly affected the protease stability.

AD05 is a SARS-CoV-2 main protease (M^pro) inhibitor with an IC₅₀ of 306.5 nM. AD05 exhibits antiviral activity against wild-type SARS-CoV-2 in host cells without inducing significant cytotoxicity. AD05 can be used in studies related to SARS-CoV-2 infection.

AD06 is a SARS-CoV-2 main protease (M^pro) inhibitor with an IC₅₀ of 163.3 nM. AD06 undergoes nucleophilic attack by deprotonated Cys145, thereby blocking viral replication. AD06 inhibits the activity of wild-type SARS-CoV-2 and shows no significant cytotoxicity in mammalian cells. AD06 can be used in studies related to SARS-CoV-2 infection.

SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC₅₀ of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells.

JMX0207 is an orally active flavivirus NS2B-NS3 protease inhibitor. JMX0207 showed an IC_50-SLC of 1.3 μM for blocking NS2B-NS3 protein interaction and an IC_50-pro of 8.2 μM for inhibiting protease catalytic activity.. JMX0207 directly binds viral NS3 protease at the NS2B-NS3 interface with a K_d of 1.1 μM, blocks viral polyprotein precursor processing, suppresses viral RNA replication and viral protein production. JMX0207 can be used for the study of Zika virus infection and Dengue virus infection.

YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PL^pro). YL1004 shows an IC₅₀ of 17.5 nM and a K_i of 2.3 nM against PL^pro, with an in vitro anti-SARS-CoV-2 EC₅₀ of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PL^pro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection).

L-Lysine-¹⁵N-1 (dihydrochloride) is the ¹⁵N-labeled L-Lysine. L-lysine is an essential amino acid with important roles in connective tissues and carnitine synthesis, energy production, growth in children, and maintenance of immune functions.

NS2B/NS3-IN-4 (Compound 34e) is an allosteric DENV2 and ZIKV NS2B/NS3 protease inhibitor with IC₅₀ values of 0.69 µM and 1.04 µM against DENV2 and ZIKV NS2B/NS3 proteases, respectively.